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OBJECTIVES: The prophylactic use of antimicrobial agents is recommended for 
the prevention of a variety of post-operative infections, which represent 25% of 
all nosocomial infections in hospitals. Inappropriate antimicrobial prophylaxis 
adds to the pressure on microbial ecology within the hospital, and increases the 
risk of antimicrobial resistance. Several factors can account for ‘antimicrobial 
inappropriateness’. The aim of this study was to evaluate the appropriateness of 
surgical antimicrobial prophylaxis in a private tertiary care hospital. METHODS: 
The data on surgical prophylactic antimicrobial utilization was collected 
retrospectively from Surgical Intensive Care Unit (SICU), Surgical orthopaedic 
ICU-1 (SPICU-1), Surgical orthopaedic ICU-2 (SPICU-2), Neuro Surgery ICU (NSICU) 
and Obstetric ward (gynae surgery). The assessment was done on the basis of 
choice of antibiotic, the time it was administered and the duration for which it 
was given, in accordance with the hospital guidelines. RESULTS: A total number 
of 478 patients were analyzed in different surgical ICUs and Obstetric ward. The 
percentage of appropriateness in selecting antibiotics was found to be 98.5% in 
SPICU-2, followed by 84.6% in NSICU, 74.5% in SPICU-1, 71.6% in SICU and least in 
Obstetric ward with 52.6%. The timing of antibiotic administration was best in 
SICU (83% appropriateness) and least in Obstetric ward (26% appropriateness). 
The appropriate duration of prophylaxis was found to be 100% in SPICU-1 and 
Obstetric ward, while inappropriate duration of prophylaxis 96.6% in SPICU-2. 
CONCLUSIONS: Overall the percentage of appropriate selection of AMAs and 
their timing of administration was fair. The appropriateness of surgical 
prophylaxis with respect to duration was best in SPICU-1 and Obstetric ward. 
These results are encouraging and will help the hospital to achieve ‘completely 
appropriate’ surgical prophylaxis.  
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OBJECTIVES: One medication adherence measure for Medicare Part D programs 
by Centers for Medicare and Medicaid Services is the receipt of angiotensin-
converting enzyme inhibitor or angiotensin receptor blocker (ACE/ARB) among 
patients with diabetes and hypertension. The objectives of this study were: 1) To 
determine the rate of receiving ACE/ARB among Medicare beneficiaries  
with diabetes and hypertension, and 2) To identify the predictors of receiving 
ACE/ARB in this population. METHODS: The study population was Medicare 
beneficiaries diagnosed with diabetes and hypertension from the National 
Ambulatory Medical Care Survey and National Hospital Ambulatory Medical  
Care Survey-Outpatient Department, from 2007 to 2009. Predictors of receiving 
ACE/ARB were determined using bivariate and multivariate logistic regression 
analysis. The Andersen's Behavioral Model of Health Services Utilization was 
used to identify patient characteristics for the multivariate analysis. RESULTS: Of 
the 6311 Medicare outpatient and physician office visits with a diagnosis of 
hypertension and diabetes, 40.7% visits received an ACE/ARB. Bivariate analysis 
found higher rate of receiving ACE/ARB for visits made to primary care physician 
compared to non-primary care physician visits (62.9% vs. 37.1%; P<0.05). 
Adjusted multivariate analyses indicated that patient visits made to the primary 
care physicians were more likely to receive ACE/ARB compared to non-primary 
care physician visits (Odds Ratio [OR]: 1.96; 95% Confidence Interval [CI]: 1.59-
2.43), and visits by patients belonging to zip codes with median household 
income within Quartile 2 ($32,794-$40,626), were more likely to receive ACE/ARB 
compared to visits by patients belonging to zip codes with median household 
income within Quartile 1 (< $32,793, OR: 1.45; 95% CI: 1.13-1.87). CONCLUSIONS: 
Fewer than half of the outpatient visits by Medicare beneficiaries with diabetes 
and hypertension received ACE/ARB. Promoting evidence-based medicine and 
increasing access to primary care may have the potential to increase the rates of 
receiving ACE/ARB for Medicare beneficiaries with diabetes and hypertension.  
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OBJECTIVES: With the introduction of new methods such as indirect comparison 
and complex economic modeling, the presentation of evidence on effectiveness, 
safety and cost effectiveness to decision makers, who have different levels of 
understanding of these methods, can be challenging. The CCNMA developed a 
framework for presenting such complex evidence from a report on New Oral 
Anticoagulants (NOACs) versus Warfarin for Stroke Prevention in Atrial Fibrillation. The 
purpose of the framework is to provide a concise summary of best available 
research evidence to inform judgments about reimbursement recommendations. 
METHODS: A systematic review of the effects of NOACs compared to warfarin 
was performed using standard Cochrane methods. This information was used to 
conduct adjusted indirect comparisons (i.e. Bayesian mixed-treatment 
comparison network meta-analysis), which were used in an economic evaluation 
to assess cost effectiveness. The effect estimates and assessments of the 
certainty of the evidence for each outcome were summarized in GRADE evidence 
profiles (using GRADEpro 3.6). This information together with results of the 
economic evaluation were summarized in frameworks for coverage decisions. 
This was done in collaboration with the GRADE Working Group and the DECIDE 
project. The frameworks also included information about the severity of the 
condition being treated, the relative importance of outcomes, the total cost 
(impact on budget), impacts on health inequities, and inappropriate use. In 
addition, the frameworks include judgments about each criterion, judgment 
about the overall balance of the desirable and undesirable consequences, 
justification for the recommendation, and implementation considerations. 
RESULTS: The frameworks were used for making reimbursement 
recommendations. CONCLUSIONS: Decision frameworks have the potential to 
provide understandable summaries of complex analyses to inform coverage 
decisions, to help ensure that key criteria are considered, to structure discussion 
and identify reasons for disagreements, and to make the basis for decisions 
transparent to those affected.  
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OBJECTIVES: The charge of catheter ablation for patients with atrial fibrillation 
(AF) in China remains unclear. The purpose of the current study was to examine 
the charge of catheter ablation for AF patients in top AF treatment centers across 
China. METHODS: The study was based on a key informant interview. Key 
informants were selected from 11 top AF treatment centers across 8 provinces of 
China. A total of 22 key informants were interviewed during the period between 
April 2011 and August 2011. Half of the key informants were senior AF specialists 
knowledgeable of catheter ablation, relevant nurses and staffs of hospital’s 
medical insurance office accounting for the other half. The interview was 
conducted face to face by trained interviewer based on an interview outline 
focusing on the charge and related issues. Analysis of interview results followed 
standard qualitative analysis methods. RESULTS: Operation of catheter ablation 
for AF patients grew quickly since 2008 and the related clinical path was issued 
by the Ministry of Health of China in 2010. However, the charge of catheter 
ablation for AF patients varied largely across the selected AF treatment centers 
with a range of RMB 45,000 to 80,000 (i.e., around USD 7200 - 12800). Catheter 
itself was not well included in the current government-valorized list. Charge 
from those government-valorized items accounted for under 10% of total charge 
in most of AF treatment centers, which was associated with heavy cross-
subsidization from the independent charge of catheters not packed in the 
government-valorized items. The choice of catheters was the key contributor to 
the variation of total charge. Charge of the second catheter ablation for recurrent 
AF also varied greatly because of catheter reuse. CONCLUSIONS: The current 
large variation of the charge of catheter ablation for AF patients in China was not 
very much in tandem with the issuance of clinical path and needs to be 
improved.  
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OBJECTIVES: Recent studies have demonstrated that up to 30% of patients never 
fill an initial prescription for antihypertensive medication. This high rate of 
primary nonadherence has direct implications for the outcomes of clinical care. 
Dramatic improvements in the availability of administrative pharmacy claims in 
the electronic health record (EHR) may promote the identification of 
nonadherent patients. The objective of this study was to characterize pharmacy 
fill patterns for a newly prescribed antihypertensive. METHODS: We conducted a 
retrospective cross-sectional study on patients prescribed a new 
antihypertensive within a large primary care practice network from 2011-2012. 
Patients were included if they had a diagnosis of hypertension or elevated blood 
pressure at the time of the new prescription and at least one practice visit within 
the previous 18 months. We excluded patients who did not have an imported 
pharmacy fill history on or after the antihypertensive index date. Pharmacy fill 
claims were pulled for the subsequent 90 days after the index date. All fills of the 
antihypertensive were then linked to the antihypertensive as found in the EHR. 
RESULTS: A total of 131 patients and 133 medications were studied. Average age 
(SD) was 55.4 (14.9), 74.8% were female, 26.7% were black and 32.8% were white. 
Most patients were prescribed one antihypertensive; 2 patients were prescribed 
two. Of the medications studied, 112 medications were linked to a fill from the 
pharmacy claims. Of the linked medications, 73.2% were filled on the index date. 
Average number of days (SD) to first fill was 4.6 (12.1); 94.6% of linked fills were 
filled within the first 30 days. CONCLUSIONS: Nearly a quarter of patients do not 
fill newly prescribed antihypertensives within 90 days of initial prescription. Our 
preliminary data suggest that the real-time availability of pharmacy claims data 
could be useful to identify nonadherent patients.  
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